 |
|
| Dow | Nasdaq | About Us | Disclaimer |  |
RSS Feed |  |
Follow us on Twitter |
|
Featured Advisors |
Healthcare & BiotechDiagnostics: Reform beneficiariesThursday, 15 April 2010 08:00 by Marc Lichtenfeld, contributing editor Investment U
However, times are changing. The new healthcare bill will enable millions more people to get their various conditions checked out. As a result, the diagnostics industry should boom. Geron (GERN): Ccancer researchTuesday, 13 April 2010 00:00 by Tom Bishop, editor BI Research Geron (NASDAQ: GERN) is developing first-in-class biopharmaceuticals for cancer and degenerative diseases (like spinal cord injury, Alzheimer’s, heart failure and diabetes) based on its core competency in telomerase biology.This is the 2009 Nobel Prize winning technology that is the key to endless cellular replication. When telomerase is present cells replicate endlessly out of control causing cancer. Kinetic Concepts: High tech healingMonday, 12 April 2010 00:00 by Lou Basenese, contributing editor The White Cap Report
When I say innovations, I’m talking about products with drug-injected, non-absorbent foams and “negative pressure” closure techniques. And we’ve identified the hands-down leader in the space – Kinetic Concepts Inc. (NYSE: KCI). Biotech bet on OncoGenex (OXGI)Friday, 09 April 2010 08:00 by John McCamant, editor The Medical technology Stock Letter
Let’s take OncoGenex (NASDAQ: OGXI) through a valuation exercise to help illustrate why we believe it is so undervalued. One of the most important elements to biotech investing is valuation. Bristol-Myers Squibb:Technical buyThursday, 08 April 2010 08:00 by Melvin Pasternak, editor Double-Digit Trading
My top stock pick in the pharma sector is Bristol-Myers Squibb (NYSE: BMY), which I believe offers a very attractive valuation and a great chart. More Articles...Page 1 of 7 << Start < Prev 1 2 3 4 5 6 7 Next > End >> |
News Flash
|
|
There are also people who avoid the doctor’s office, not because they’re afraid of needles, but because they can’t afford it.
When you think of Band-Aids, I guarantee you don’t think big profits. However, the wound care market tops $15 billion in annual sales. And the industry’s still growing at a healthy clip, thanks to high-tech innovations. 
It is often hard to know what to do when a stock group has made a large advance. While many investors tend to think that a large advance is a signal to avoid a group, this is not necessarily useful when looking at biotech stocks. 
Although the new healthcare legislation means that the pharmaceutical industry will face about $90 billion in new taxes and fees over time, the legislation also brings many benefits to pharmaceutical companies including a potentially huge influx of new customers now able to afford prescription medication through insurance coverage.